The Full Recovery of Mice (Mus Musculus C57BL/6 Strain) from Virus-induced Sarcoma After Treatment with a Complex of DDMC Delivery System and SncRNAs

Overview

Journal Noncoding RNA Res

Date 2019 Jun 14

PMID 31193489

Citations 1

Authors

Oxana V Klimenko

Alexey Sidorov

Affiliations

Soon will be listed here.

Abstract

Background: Virus-induced cellular genetic modifications result in the development of many human cancers.

Methods: In our experiments, we used the RVP3 cell line, which produce primary mouse virus-induced sarcoma in 100% of cases. Inbreed 4-week-old female C57BL/6 mice were injected subcutaneously in the interscapular region with RVP3 cells. Three groups of mice were used. For treatment, one and/or two intravenous injections of a complex of small non-coding RNAs (sncRNAs) a-miR-155, piR-30074, and miR-125b with a 2-diethylaminoethyl-dextran methyl methacrylate copolymer (DDMC) delivery system were used. The first group consisted of untreated animals (control). The second group was treated with one injection of complex DDMC/sncRNAs (1st group). The third group was treated with two injections of complex DDMC/sncRNAs (2nd group). The tumors were removed aseptically, freed of necrotic material, and used with spleen and lungs for subsequent RT-PCR and immunofluorescence experiments, or stained with Leishman-Romanowski dye.

Results: As a result, the mice fully recovered from virus-induced sarcoma after two treatments with a complex including the DDMC vector and a-miR-155, piR-30074, and miR-125b. In vitro studies showed genetic and morphological transformations of murine cancer cells after the injections.

Conclusions: Treatment of virus-induced sarcoma of mice with a-miR-155, piR-30074, and miR-125b as active component of anti-cancer complex and DDMC vector as delivery system due to epigenetic-regulated transformation of cancer cells into cells with non-cancerous physiology and morphology and full recovery of disease.

Citing Articles

Perspectives on the Use of Small Noncoding RNAs as a Therapy for Severe Virus-Induced Disease Manifestations and Late Complications.

Klimenko O Bionanoscience. 2022; 12(3):994-1001.

PMID: 35529531 PMC: 9066397. DOI: 10.1007/s12668-022-00977-z.

References

Assumpcao C, Calcagno D, Thomaz Araujo T, Dos Santos S, Santos A, Riggins G . The role of piRNA and its potential clinical implications in cancer. Epigenomics. 2015; 7(6):975-84. PMC: 4750480. DOI: 10.2217/epi.15.37. View

Svoboda J, Plachy J, Hejnar J, Karakoz I, Guntaka R, Geryk J . Tumor induction by the LTR, v-src, LTR DNA in four B (MHC) congenic lines of chickens. Immunogenetics. 1992; 35(5):309-15. DOI: 10.1007/BF00189893. View

Kaetzel M, Chan H, Dubinsky W, Dedman J, Nelson D . A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J Biol Chem. 1994; 269(7):5297-302. View

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

Willimott S, Wagner S . miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem. 2011; 287(4):2608-17. PMC: 3268420. DOI: 10.1074/jbc.M111.285718. View

Shen R, Wang Y, Wang C, Yin M, Liu H, Chen J . MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res. 2015; 7(10):2115-26. PMC: 4656789. View

Weiss R, Vogt P . 100 years of Rous sarcoma virus. J Exp Med. 2011; 208(12):2351-5. PMC: 3256973. DOI: 10.1084/jem.20112160. View

Irby R, Yeatman T . Role of Src expression and activation in human cancer. Oncogene. 2000; 19(49):5636-42. DOI: 10.1038/sj.onc.1203912. View

Wang X, Chen Z . MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation. Int J Mol Med. 2015; 35(3):839-46. DOI: 10.3892/ijmm.2015.2071. View

10.

Svoboda J . Cell Association in Rous Sarcoma Virus (RSV) Rescue and Cell Infection. Folia Biol (Praha). 2015; 61(5):161-7. DOI: 10.14712/fb2015061050161. View

11.

Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G . Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila). 2011; 4(10):1698-709. PMC: 3940389. DOI: 10.1158/1940-6207.CAPR-11-0267. View

12.

Varmus H, Bishop J, Vogt P . Appearance of virus-specific DNA in mammalian cells following transformation by Rous sarcoma virus. J Mol Biol. 1973; 74(4):613-26. DOI: 10.1016/0022-2836(73)90052-1. View

13.

Boccardo E, Villa L . Viral origins of human cancer. Curr Med Chem. 2007; 14(24):2526-39. DOI: 10.2174/092986707782023316. View

14.

Hill W, Kaetzel M, Kishore B, Dedman J, Zeidel M . Annexin A4 reduces water and proton permeability of model membranes but does not alter aquaporin 2-mediated water transport in isolated endosomes. J Gen Physiol. 2003; 121(5):413-25. PMC: 2217383. DOI: 10.1085/jgp.200308803. View

15.

Martin G . The road to Src. Oncogene. 2004; 23(48):7910-7. DOI: 10.1038/sj.onc.1208077. View

16.

Kozak M . An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987; 15(20):8125-48. PMC: 306349. DOI: 10.1093/nar/15.20.8125. View

17.

Sohma H, Creutz C, Gasa S, Ohkawa H, Akino T, Kuroki Y . Differential lipid specificities of the repeated domains of annexin IV. Biochim Biophys Acta. 2001; 1546(1):205-15. DOI: 10.1016/s0167-4838(01)00140-6. View

18.

Geryk J, Mazo A, Svoboda J, Hlozanek I . Replication of transformation-defective mutants of the Prague strain of Rous sarcoma virus and isolation of a td mutant from duck-adapted PR-RSV-C. Folia Biol (Praha). 1980; 26(1):34-41. View

19.

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

20.

Klimenko O, Shtilman M . Reprogramming of CaCo2 colorectal cancer cells after using the complex of poly-(N-vinylpyrrolidone) with small non-coding RNAs. Toxicol Rep. 2019; 6:186-192. PMC: 6405903. DOI: 10.1016/j.toxrep.2019.02.001. View